US Pharma MarketingAmylin design debate heats up as Lilly's crucial mid-stage weight loss data near
In the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agonist to ...
In the amylin race, drug design appears to be a key differentiator.
Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agonist to ...
Source: Endpoints News